Navigation Links
Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
Date:4/26/2011

tment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").  The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy.
  • Met with officials of the FDA's OND and presented arguments supporting CTI's belief that the data contained in its NDA 22-481 supports the conclusion that pixantrone is effective for its planned use. CTI expects a decision on its appeal during the second quarter of 2011.
  • Received the day 120 list of questions from the EMA relating to our MAA for pixantrone in Europe.

  • For the quarter ended March 31, 2011, total operating expenses decreased to $20.1 million compared to $25.8 million for the same period in 2010.  Research and development expenses increased to $11.5 million in the quarter ended March 31, 2011 compared to $7.4 million for the same period in 2010 due to a one-time upfront payment of $5.0 million related to the licensing of tosedostat from Chroma in 2011. Selling, general and administrative expenses decreased to $8.6 million in the quarter ended March 31, 2011 compared to $18.4 million for the same period in 2010 primarily related to a decrease in non-cash equity based compensation. Net loss attributable to common shareholders was $51.0 million ($0.06 per share) for the quarter ended March 31, 2011 compared to a net loss attributable to common shareholders of $44.2 million ($0.07 per share) for the same period in 2010. The increase in net loss attributable to common shareholders is mainly due to an increase in non-cash deemed dividends on preferred stock related to financing activities.

    CTI had approximately $43.8 million in cash and cash equivalents as of March 31, 2011.Conference Call InformationOn Wednesday, April 27, 2011, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m.
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
    2. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
    3. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
    4. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
    5. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
    6. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
    7. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
    8. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
    9. BioMarin Acquires ZyStor Therapeutics, Inc.
    10. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
    11. Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... , Aug. 28, 2014 The Leukemia ... a partnership to advance an experimental cancer vaccine ... an asymptomatic stage of myeloma. The ... through which LLS forges collaborations with biotechnology companies ... OncoPep is developing a vaccine, PVX-410, ...
    (Date:8/28/2014)... ANTONIO , Aug. 28, 2014 GenSpera, ... for the treatment of cancer, announces the recent publication ... journal Steroids . The recent article ... reviews the evolution and development of GenSpera,s prodrug technology platform ... of thapsigargin (from the plant Thapsia garganica ) ...
    (Date:8/28/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) a leading ... for the eye, today announced that management will present at ... Palace Hotel on Wednesday, September 3 at 7:15 a.m. PT/10:15 ... CEO will offer a general overview of the Company,s current ... by Steve Brown , CFO, and Sam Gesten ...
    Breaking Medicine Technology:The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3STAAR Surgical To Present At The Baird 2014 Health Care Conference 2
    ... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... of the largest network of radiotherapy and diagnostic imaging ... directors approved a share repurchase program, effective immediately. ... States federal securities laws, Concord Medical is authorized to ...
    ... Sept. 29, 2011 The Educational Review System held ... 28 at the Meyedenbauer Center in Bellevue, WA. Attendees ... pharmacy thought leaders discuss the challenges of pediatric medications, ... the 2010 recipient of the Institute for Safe Medication ...
    Cached Medicine Technology:Concord Medical Services Announces Share Repurchase Program 2Concord Medical Services Announces Share Repurchase Program 3
    (Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
    (Date:8/28/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, today ... Services, and Chris Greco, Manager, Comparator and Ancillary ... Active Control Clinical Trials” at the forthcoming US ... the 9th – 10th September, 2014 in Philadelphia, ...
    (Date:8/28/2014)... vaccine to prevent Ebola virus disease will begin next ... Diseases (NIAID), part of the National Institutes of Health. ... of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) ... to generate an immune system response in healthy adults. ... in Bethesda, Maryland. , The study is the first ...
    (Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
    (Date:8/28/2014)... over who identify themselves as ,old, feel worse about ... have lower value than younger age groups. , New ... ,Being old and ill, across different countries: social status, ... from the European Social Survey. Respondents, who were all ... health., The researchers found that those living in societies ...
    Breaking Medicine News(10 mins):Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Drug shows promise for subset of stage III colon cancer patients 2
    ... ALEXANDRIA, Va., July 23 The model for,person-centered long ... to testimony submitted today to the US Senate Special ... care that embraces choice,independence and the opportunity for seniors ... Richard Grimes, the President and CEO,of the Assisted Living ...
    ... had heart trouble, the worse their performance , , WEDNESDAY, July ... heart disease seem to fare worse on measures of cognitive ... disease, the worse the performance in such mental processes as ... the July 23 issue of the European Heart Journal ...
    ... Three years after Hurricane Katrina devastated parts of the Gulf ... Public Health Project on the Public and Biological Security shows ... they are very prepared if a major hurricane were to ... worries of respondents threatened or hit by Hurricane Katrina are ...
    ... Cohen Hired As New CEO, ATLANTA, July 23 ... MELCO Investments LLC, a private business and,real estate investment ... a,substantial capital investment in GMCG. Along with the investment, ... leading colon and rectal,surgeons, as its new CEO., ...
    ... and Medicare Rules Highlighted; a Focus on Preventing ... Hospital-acquired Conditions, LANSING, ... a national leader in clinical risk management,practice and patient safety programs ... for its annual risk,management conference., The conference will take place ...
    ... the #1 Healthiest City to,Live and Retire In -, ... voice for 50+ Americans and the world,s largest-circulation,magazine with ... ten,healthiest cities to live and retire in with Ann ... Fargo, ND taking the top five rankings.,Featured in the ...
    Cached Medicine News:Health News:ASSISTED LIVING: The Model for Person-Centered Long Term Care 2Health News:Coronary Disease Dulls Cognitive Skills 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 2Health News:Hurricane preparedness survey: Worries about drinking water and medical care 3Health News:Hurricane preparedness survey: Worries about drinking water and medical care 4Health News:Hurricane preparedness survey: Worries about drinking water and medical care 5Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 2Health News:Greater Medical Center Group Receives Major Funding From MELCO Investments 3Health News:The Risk Management and Patient Safety Institute Announces 2008/2009 Annual Risk Management Conference, Dates 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 2Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 3Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 4Health News:AARP the Magazine Names the Top 10 Healthiest Places to Live in America 5
    6 mm, 45 degree upwards, detachable....
    Aaron 950 is a high frequency desiccator with cut....
    The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
    The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
    Medicine Products: